AIM: Anti-Saccharomyces cerevisiae antibodies (ASCA), anti-nuclear associated anti-neutrophil antibodies (NANA) and antibodies to exocrine pancreas (PAB), are serological tools for discriminating Crohn's disease (CrD) and ulcerative colitis (UC). Like CrD, coeliac disease (CoD) is an inflammatory bowel disease (IBD) associated with (auto) antibodies. Performing a multicenter study we primarily aimed to determine the performance of ASCA, NANA and PAB tests for IBD diagnosis in children and adults, and secondarily to evaluate the prevalence of these markers in CoD. METHODS: Sera of 109 patients with CrD, 78 with UC, 45 with CoD and 50 healthy blood donors were retrospectively included. ASCA, NANA and PAB were detected by indirect immunofluorescence (IIF). RESULTS: ASCA+/NANA- profile displayed a positive predictive value of 94.2% for CrD. Detection of ASCA was correlated with a more severe clinical profile of CrD and treatment of the disease did not influence their serum levels. ASCA positivity was found in 37.9% of active CoD. PAB were found in 36.7% CrD and 13.3% CoD patients and were not correlated with clinical features of CrD, except with an early onset of the disease. Fifteen CrD patients were ASCA negative and PAB positive. CONCLUSION: ASCA and PAB detected by IIF are specific markers for CrD although their presence does not rule out a possible active CoD. The combination of ASCA, NANA and PAB tests improves the sensitivity of immunological markers for CrD. Repeating ASCA, NANA, and PAB testing during the course of CrD has no clinical value.
AIM: Anti-Saccharomyces cerevisiae antibodies (ASCA), anti-nuclear associated anti-neutrophil antibodies (NANA) and antibodies to exocrine pancreas (PAB), are serological tools for discriminating Crohn's disease (CrD) and ulcerative colitis (UC). Like CrD, coeliac disease (CoD) is an inflammatory bowel disease (IBD) associated with (auto) antibodies. Performing a multicenter study we primarily aimed to determine the performance of ASCA, NANA and PAB tests for IBD diagnosis in children and adults, and secondarily to evaluate the prevalence of these markers in CoD. METHODS: Sera of 109 patients with CrD, 78 with UC, 45 with CoD and 50 healthy blood donors were retrospectively included. ASCA, NANA and PAB were detected by indirect immunofluorescence (IIF). RESULTS: ASCA+/NANA- profile displayed a positive predictive value of 94.2% for CrD. Detection of ASCA was correlated with a more severe clinical profile of CrD and treatment of the disease did not influence their serum levels. ASCA positivity was found in 37.9% of active CoD. PAB were found in 36.7% CrD and 13.3% CoD patients and were not correlated with clinical features of CrD, except with an early onset of the disease. Fifteen CrD patients were ASCA negative and PAB positive. CONCLUSION: ASCA and PAB detected by IIF are specific markers for CrD although their presence does not rule out a possible active CoD. The combination of ASCA, NANA and PAB tests improves the sensitivity of immunological markers for CrD. Repeating ASCA, NANA, and PAB testing during the course of CrD has no clinical value.
Authors: S Vermeire; M Peeters; R Vlietinck; S Joossens; E Den Hond; V Bulteel; X Bossuyt; B Geypens; P Rutgeerts Journal: Inflamm Bowel Dis Date: 2001-02 Impact factor: 5.325
Authors: Sofie Joossens; Walter Reinisch; Séverine Vermeire; Boualem Sendid; Daniel Poulain; Marc Peeters; Karel Geboes; Xavier Bossuyt; Peggy Vandewalle; Georg Oberhuber; Harald Vogelsang; Paul Rutgeerts; Jean-Frédéric Colombel Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: Jan G M C Damoiseaux; Bas Bouten; Annick M L W Linders; Jos Austen; Caroline Roozendaal; Maurice G V M Russel; Pierre-Philippe Forget; Jan Willem Cohen Tervaert Journal: J Clin Immunol Date: 2002-09 Impact factor: 8.317
Authors: I Fresko; S Ugurlu; F Ozbakir; A Celik; S Yurdakul; V Hamuryudan; H Yazici Journal: Clin Exp Rheumatol Date: 2005 Jul-Aug Impact factor: 4.473
Authors: Devendra K Amre; Philippe Lambrette; Liliane Law; Alfreda Krupoves; Virginie Chotard; Florin Costea; Guy Grimard; David Israel; David Mack; Ernest G Seidman Journal: Am J Gastroenterol Date: 2006-05 Impact factor: 10.864
Authors: P Muratori; L Muratori; M Guidi; S Maccariello; G Pappas; R Ferrari; P Gionchetti; M Campieri; F B Bianchi Journal: Clin Exp Immunol Date: 2003-06 Impact factor: 4.330
Authors: James Markowitz; Subra Kugathasan; Marla Dubinsky; Ling Mei; Wallace Crandall; Neal LeLeiko; Maria Oliva-Hemker; Joel Rosh; Jonathan Evans; David Mack; Anthony Otley; Marian Pfefferkorn; Ron Bahar; Eric Vasiliauskas; Ghassan Wahbeh; Gary Silber; J Antonio Quiros; Iwona Wrobel; Justin Nebel; Carol Landers; Yoanna Picornell; Stephan Targan; Trudy Lerer; Jeffrey Hyams Journal: Inflamm Bowel Dis Date: 2009-05 Impact factor: 5.325
Authors: Emily G Severance; Armin Alaedini; Shuojia Yang; Meredith Halling; Kristin L Gressitt; Cassie R Stallings; Andrea E Origoni; Crystal Vaughan; Sunil Khushalani; F Markus Leweke; Faith B Dickerson; Robert H Yolken Journal: Schizophr Res Date: 2012-03-24 Impact factor: 4.939
Authors: Tyson R Chiaro; Ray Soto; W Zac Stephens; Jason L Kubinak; Charisse Petersen; Lasha Gogokhia; Rickesha Bell; Julio C Delgado; James Cox; Warren Voth; Jessica Brown; David J Stillman; Ryan M O'Connell; Anne E Tebo; June L Round Journal: Sci Transl Med Date: 2017-03-08 Impact factor: 17.956
Authors: Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres Journal: World J Gastroenterol Date: 2014-05-07 Impact factor: 5.742